Suppressing estrogen to treat lung cancer

Patel Lung cancer is the leading cause of death in women, and the hormone estrogen has been shown to play a role in the growth of lung tumors.

With Masonic support, Manish Patel, D.O., part of the U’s hematology, oncology, and transplantation faculty is exploring the impact of estrogen signaling on lung cancer immunotherapy.

So far, Patel’s team has found that while immunotherapy has benefits, estrogen receptors in lung tumors might interfere with its effectiveness. They are now exploring whether a breast cancer drug that suppresses estrogen, called exemestane, might increase the potency of immunotherapy against lung cancer. Their next big step will be to launch a clinical trial that tests this combination treatment.

Support from Minnesota Masonic Charities has allowed us to gain insight into how estrogen signaling might impact a woman’s response to lung cancer immunotherapy.

 

Related

Balbo Lab
In addition to causing side effects such as vomiting or hair loss, chemotherapy is thought to play a significant role in how patients respond to... Read more
Anja Bielinsky
Cancer is a genetic disease, occurring when inherited or environmental factors corrupt the DNA in cells. Although scientists have made strides in... Read more
David Potter
With Masonic support, David Potter, M.D., Ph.D., a hematology, oncology, and transplantation faculty member, is working to improve outcomes for women... Read more